Clinical Trial Update: Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients [NA]

View source ↗

Summary

Completed clinical trial evaluating the NaviFUS system as an add-on to Bevacizumab for recurrent glioblastoma, reporting efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: NaviFUS Corporation | Conditions: Glioblastoma Multiforme, Glioblastoma | NA | Status: COMPLETED